{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:48:55Z","timestamp":1791748135882,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZLRK202529"],"award-info":[{"award-number":["ZLRK202529"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","award":["Z221100007422087"],"award-info":[{"award-number":["Z221100007422087"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.suronc.2026.102480","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:58:22Z","timestamp":1781308702000},"page":"102480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epidemiology and treatment options for cervical cancer patients aged &lt;25\u202fYears based on SEER database and real world research"],"prefix":"10.1016","volume":"67","author":[{"given":"Ming-Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiliminuer","family":"Abulajiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tao","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.suronc.2026.102480_bib1","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Global Health"},{"issue":"3","key":"10.1016\/j.suronc.2026.102480_bib2","first-page":"322","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"issue":"5","key":"10.1016\/j.suronc.2026.102480_bib3","first-page":"321","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American cancer society","volume":"70","author":"Fontham","year":"2020","journal-title":"Ca - Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.suronc.2026.102480_bib4","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/S1470-2045(24)00262-6","article-title":"Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE","volume":"25","author":"Morice","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2026.102480_bib5","doi-asserted-by":"crossref","first-page":"663.e1","DOI":"10.1016\/j.ajog.2024.02.012","article-title":"Fertility-sparing surgery vs standard surgery for early-stage cervical cancer: difference in 5-year life expectancy by tumor size","volume":"230","author":"Jorgensen","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.suronc.2026.102480_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"3","key":"10.1016\/j.suronc.2026.102480_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.14735\/amko2019224","article-title":"Current FIGO staging for carcinoma of the cervix uteri and treatment of particular stages","volume":"32","author":"Sehnal","year":"2019","journal-title":"Klin. Onkol."},{"key":"10.1016\/j.suronc.2026.102480_bib8","series-title":"Female Genital Tumours","year":"2020"},{"issue":"3","key":"10.1016\/j.suronc.2026.102480_bib9","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2026.37.e36","article-title":"Update of incidence and survival in patients with cervical cancer in the United States from 2000 to 2021","volume":"37","author":"Wang","year":"2026","journal-title":"Journal of Gynecologic Oncology"},{"issue":"2","key":"10.1016\/j.suronc.2026.102480_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2024.22169","article-title":"Cervical cancer mortality among US women younger than 25 years, 1992-2021","volume":"333","author":"Dorali","year":"2025","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.suronc.2026.102480_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/djz227","article-title":"Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis","volume":"112","author":"Burger","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.suronc.2026.102480_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1470-2045(23)00185-7","article-title":"The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a chinese multicentre registry","volume":"24","author":"Chu","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2026.102480_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1386294","article-title":"State of the art of cervical cancer treatment in rare histologies","volume":"14","author":"Arango-Bravo","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.suronc.2026.102480_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2025.200323","article-title":"The immunological heterogeneity of squamous cell carcinoma and adenocarcinoma of the uterine cervix: a systematic review","volume":"20","author":"Strikwerda","year":"2025","journal-title":"Tumour Virus Res."},{"key":"10.1016\/j.suronc.2026.102480_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211051558","article-title":"Clinicopathological features and survival of adolescent and young adults with cervical cancer","volume":"28","author":"Pan","year":"2021","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.suronc.2026.102480_bib16","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.3802\/jgo.2023.34.e64","article-title":"A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial)","volume":"34","author":"Qiu","year":"2023","journal-title":"J. Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.suronc.2026.102480_bib17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines\u00ae insights: cervical cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"11","key":"10.1016\/j.suronc.2026.102480_bib18","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1245\/s10434-017-6031-z","article-title":"2017 update on the querleu-morrow classification of radical hysterectomy","volume":"24","author":"Querleu","year":"2017","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2026.102480_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12905-022-01887-8","article-title":"Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis","volume":"22","author":"Laios","year":"2022","journal-title":"BMC Women's Health"},{"issue":"3","key":"10.1016\/j.suronc.2026.102480_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266001","article-title":"Clinical outcome of FIGO 2018 stage IB3\/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: a retrospective comparison with concurrent chemoradiotherapy","volume":"17","author":"Zeng","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.suronc.2026.102480_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2022.12.002","article-title":"Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer","volume":"169","author":"Li","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.suronc.2026.102480_bib22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/ijgc-2023-004669","article-title":"Fertility sparing therapy in women with lymph node negative cervical cancer >2cm - oncologic and fertility outcomes of neoadjuvant chemotherapy followed by radical vaginal trachelectomy","volume":"33","author":"Plaikner","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2026.102480_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.suronc.2026.102480_bib24","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/JCO.22.02852","article-title":"Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2-IIB cervical cancer: EORTC-55994","volume":"41","author":"Kenter","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.suronc.2026.102480_bib25","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/cancers16142542","article-title":"Locally advanced cervical cancer: neoadjuvant treatment versus standard radio-chemotherapy-an updated meta-analysis","volume":"16","author":"Ronsini","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.suronc.2026.102480_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12905-024-03215-8","article-title":"The role of neoadjuvant chemotherapy before radical surgery in stage IB2\/IIA2 squamous cell cervical cancers","volume":"24","author":"Alci","year":"2024","journal-title":"BMC Women's Health"},{"issue":"1","key":"10.1016\/j.suronc.2026.102480_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12967-024-05482-3","article-title":"Evaluation of pathological response to neoadjuvant chemotherapy in locally advanced cervical cancer","volume":"22","author":"Wei","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.suronc.2026.102480_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0340963","article-title":"Fertility-sparing surgery with neoadjuvant chemotherapy in early and locally advanced cervical cancer: a clinical protocol","volume":"21","author":"Tanioka","year":"2026","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.suronc.2026.102480_bib29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10462","key":"10.1016\/j.suronc.2026.102480_bib30","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.suronc.2026.102480_bib31","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10434","key":"10.1016\/j.suronc.2026.102480_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.suronc.2026.102480_bib33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.suronc.2026.102480_bib34","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.3802\/jgo.2024.35.e65","article-title":"Evolving standards and future directions for systemic therapies in cervical cancer","volume":"35","author":"Ang","year":"2024","journal-title":"J. Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.suronc.2026.102480_bib35","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3390\/jcm13154458","article-title":"New frontiers in locally advanced cervical cancer treatment","volume":"13","author":"Massobrio","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.suronc.2026.102480_bib36","article-title":"Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740426001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740426001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:34:15Z","timestamp":1791747255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740426001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0960740426001313"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2026.102480","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and treatment options for cervical cancer patients aged <25\u202fYears based on SEER database and real world research","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2026.102480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102480"}}